Also trades as: 0JQ2.L (LSE) · $vol 0M
KALA NASDAQ
KALA BIO, Inc.
1W: -19.1%
1M: -26.3%
3M: -75.0%
YTD: -98.8%
1Y: -99.4%
3Y: -99.9%
5Y: -100.0%
$0.39
-0.03 (-8.20%)
Weekly Expected Move ±16.6%
$0
$0
$0
$0
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
17 relationships17
As Filer
counterparties named
0
As Counterparty
mentioned by others
5
Rel. Types
2021-11-15
Earliest Filing
2026-03-04
Latest Filing
partner: 8
acquirer: 4
investor: 3
target: 1
customer: 1
Counterparties (Filed by KALA)
17 relationshipsCompanies named in KALA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| 2624465 Ontario Inc. o/a Younet AI | — | partner | KALA BIO, Inc. entered into a Platform Development and Exclusive License Agreement to obtain a worldwide exclusive licen | 2026-03-04 | View |
| H.C. Wainwright & Co., LLC | — | partner | Sales agent for the Company's At The Market Offering program | 2026-01-08 | View |
| Baker Bros. Advisors LP | — | investor | Settlement agreement to resolve claims relating to participation rights under prior financing arrangements. | 2026-01-06 | View |
| LifeSci Capital LLC | — | investor | Settlement agreement to settle payment obligations for financial advisory services. | 2026-01-06 | View |
| Delaware IR LLC | — | partner | Consulting and settlement agreement for marketing and advertising services. | 2026-01-06 | View |
| Combangio, Inc. | — | partner | Co-borrower under the Loan Agreement and party to the Oxford Loan Settlement Agreement. | 2025-11-25 | View |
| David Lazar | — | investor | Investor in the Convertible Loan Agreement and Securities Purchase Agreement; appointed CEO. | 2025-11-25 | View |
| Jefferies LLC | JEF | partner | Sales agent for open market sale of common stock | 2023-01-19 | View |
| Combangio, Inc. | — | partner | Wholly-owned subsidiary of the Company party to loan agreement | 2023-01-19 | View |
| Alcon Pharmaceuticals Ltd. | ALC | acquirer | Purchased rights to EYSUVIS, INVELTYS, and AMPPLIFY technology from Kala Pharmaceuticals | 2022-07-08 | View |
| Alcon Vision, LLC | ALC | acquirer | Purchased rights to EYSUVIS, INVELTYS, and AMPPLIFY technology from Kala Pharmaceuticals | 2022-07-08 | View |
| Combangio, Inc. | — | partner | Collateral agent in the Loan and Security Agreement with Kala Pharmaceuticals | 2022-07-08 | View |
| Alcon Pharmaceuticals Ltd. | ALC | acquirer | Purchased rights to manufacture, sell, and commercialize EYSUVIS and INVELTYS along with AMPPLIFY technology. | 2022-05-23 | View |
| Alcon Vision, LLC | ALC | acquirer | Purchased rights to manufacture, sell, and commercialize EYSUVIS and INVELTYS along with AMPPLIFY technology. | 2022-05-23 | View |
| Combangio, Inc. | — | target | Target company acquired by Kala Pharmaceuticals, Inc. in a merger agreement. | 2021-11-15 | View |
| Fortis Advisors LLC | — | partner | Solely in its capacity as Combangio Equityholder Representative in the Merger Agreement. | 2021-11-15 | View |
| Columbia Massachusetts Arsenal Office Properties, LLC | — | customer | Landlord that entered into a Lease Termination Agreement with Kala Pharmaceuticals, Inc. | 2021-11-15 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-10 | Material Agreement; Exhibits | Agreement | View |
| 2026-09-09 | Other Events | View | |
| 2026-08-28 | Delisting Notice | View | |
| 2026-07-23 | Other Events; Exhibits | View | |
| 2026-03-04 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2026-02-20 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-02-05 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-02-02 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Changes in Contro | Agreement | View |
| 2026-01-23 | Notice of Delisting or Transfer | View | |
| 2026-01-08 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2026-01-06 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2026-01-02 | Other Events | View | |
| 2025-12-29 | Changes in Registrant's Certifying Accountant; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-12-16 | Shareholder Nominations; Other Events; Financial Statements and Exhibits | View | |
| 2025-12-16 | Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits | View | |
| 2025-12-05 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-11-25 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Creation of | Agreement | View |
| 2025-11-12 | Notice of Delisting or Transfer | View | |
| 2025-11-10 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2025-10-20 | Costs Associated with Exit or Disposal Activities; Departure/Election of Directors; Appointment of O | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR